VRDN - Company ID 0001590750
Viridian Therapeutics, Inc.DE trades as VRDN and has a market capitalization of $2.08 B, making it the #2108 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $70.85M, up 23359.9% from the prior year and net income of -$342.60M. This page tracks Viridian Therapeutics, Inc.DE through 794 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Viridian Therapeutics, Inc.DE's revenue grew from $3.48M to $70.85M, a compound annual growth rate of 39.8%. Net profit margin expanded from -496.8% to -483.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13G | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-13 |
| SCHEDULE 13D/A | - | 2026-05-13 |
| Major company event | 8-K | 2026-05-11 |
| Prospectus supplement | 424B5 | 2026-05-08 |
| Prospectus supplement | 424B5 | 2026-05-08 |
| SCHEDULE 13G | - | 2026-05-08 |
The largest companies sharing Viridian Therapeutics, Inc.DE's SEC industry classification (pharmaceutical preparations).
Viridian Therapeutics, Inc.DE (VRDN) has a market capitalization of $2.08 B as of 2026-07-09, ranking #2108 among US-listed companies.
Viridian Therapeutics, Inc.DE reported revenue of $70.85M for fiscal year 2025, an increase of 23359.9% year over year.
In its latest fiscal year Viridian Therapeutics, Inc.DE reported a net loss of $342.60M.